SEC Form 4 · accession 0001682852-26-000153

Moderna, Inc. · MRNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Stephane Bancel

Officer — Chief Executive Officer · Director

Period of report

Aug 5, 2026

Accepted (ET)

Aug 7, 2026 · 4:11 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001682852

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 5, 2026	M	499,246	$19.15	A	6,687,037	D
Common Stock^F2	Aug 5, 2026	S	147,473	$56.21	D	6,539,564	D
Common Stock^F3	Aug 5, 2026	S	124,838	$56.96	D	6,414,726	D
Common Stock^F4	Aug 5, 2026	S	39,891	$58.12	D	6,374,835	D
Common Stock^F5	Aug 5, 2026	S	187,044	$58.79	D	6,187,791	D
Common Stock	Aug 6, 2026	M	252,469	$19.15	A	6,440,260	D
Common Stock^F6	holding	—	—		—	9,210,686	I	See Footnote
Common Stock^F7	holding	—	—		—	6,564,880	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$19.15	Aug 5, 2026	M	370,853	D	—	Aug 10, 2026	Common Stock	370,853	187,541	D
Stock Option (Right to Buy)^F8	$19.15	Aug 5, 2026	M	128,393	D	—	Aug 10, 2026	Common Stock	128,393	64,928	D
Stock Option (Right to Buy)^F8	$19.15	Aug 6, 2026	M	187,541	D	—	Aug 10, 2026	Common Stock	187,541	0	D
Stock Option (Right to Buy)^F8	$19.15	Aug 6, 2026	M	64,928	D	—	Aug 10, 2026	Common Stock	64,928	0	D

Explanation of responses

F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.
F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F7These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F8This option is fully vested and exercisable.